World News Insights
1-3 Minute Gist
Search, personalize, or simply browse. Follow the world around you from gist and context to insights.
Who we are | Our Credo | Ways of using Lyrarc | FAQ | Send Feedback | First Letter From the Editor
Sign up. It's free and easy to use
Create an account
to personalize your feed of articles and topics.
All Topics Article
AARP Study Says Price of Popular Drugs Rose 26%
Keywords:
A study by AARP of 514 brand name and generic drugs between 2005 and 2009, shows that generic drug prices went down an average of 31% during this period, and brand name drug prices went up by 41%. One of the authors of the report says that it is important to look at individual drug prices and not studies showing total spending on drugs, because this is a significant cost for people paying out-of-pocket, It drives up insurance premiums, and pushes retirees into coverage gaps in Medicare Part D drug program. Analysts indicate pharmaceutical companies are increasing prices on drugs before patent expiration to get as much profit before the patents expire.
Price increases and cost of branded drugs and generic drugs- the pharmaceutical industry in 2011-2014
01/11/2010
Higer cost of specialty drugs for cancer, MS, other diseases, and the efforts by companies to squeeze profits from a shrinking branded portfolio push costs up for branded drugs. Prices of generics decline significantly. Express Scripts study shows 11% increase for branded drugs in 2011-2012 compared to 22% decrease for generics.
Grouped Articles
The Soaring Cost of a Simple Breath
New York Times 10/12/2013
AARP Study Says Price of Popular Drugs Rose 26%
New York Times 03/06/2012
Will Rising Prices for Some Generic Drugs Never End?
Wall Street Journal 11/14/2014
Washington Post 09/22/2015
Cost of Brand-Name Prescription Medicines Soaring
New York Times 11/28/2012
Beneath Budget Battle, a Health-Spending Juggernaut
Wall Street Journal 12/17/2012
Indian pharmaceutical companies and patent challenges.
07/07/2009
Grouped Articles
India Orders Bayer to License Patented Cancer Drug
New York Times 03/12/2012
India Rejects Novartis Patent Claim
Wall Street Journal 07/07/2009
India Prepares EU Trade Complaint
Wall Street Journal 08/06/2009
India-E.U. trade pact could boost AIDS treatment costs, health workers say - The Washington Post
Washington Post 02/11/2012
Indiaâs Supreme Court to Hear Dispute on Drug Patents
New York Times 03/06/2012
AARP Study Says Price of Popular Drugs Rose 26%
New York Times 03/06/2012
Intellectual property issues, pricing and the Indian pharmaceutical industry
02/11/2012
Grouped Articles
India Administers Price-Cap Dose to Drug Companies
Wall Street Journal 09/22/2014
India-E.U. trade pact could boost AIDS treatment costs, health workers say - The Washington Post
Washington Post 02/11/2012
Indiaâs Supreme Court to Hear Dispute on Drug Patents
New York Times 03/06/2012
AARP Study Says Price of Popular Drugs Rose 26%
New York Times 03/06/2012
Top Court in India Rejects Novartis Drug Patent
New York Times 04/01/2013
Meeting the cost concerns of governments and insurers. Efforts by pharmaceutical companies.
11/09/2006
Efforts by companies like GlaxoSMithKline to meet cost concerns of governments by linking pricing to the effectiveness of the drugs or treatments. Pharmaceutical pricing an issue with governments.
Grouped Articles
Wall Street Journal 11/09/2006
Glaxo Chief Charts New Growth Strategy
Wall Street Journal 06/10/2008
Pricey Drugs Put Squeeze on Doctors
Wall Street Journal 07/08/2008
Drug Makers Trim Prices for Health Overhaul
Wall Street Journal 06/22/2009
For Drug Makers, Concessions Have a Bright Side
Wall Street Journal 06/23/2009
New York Times 06/25/2009
Pharmaceutical pricing in Germany
07/08/2011
Grouped Articles
An ObamaCare Drug Preview in Germany
Wall Street Journal 07/08/2011
Austerity in Europe Puts Pressure on Drug Companies
New York Times 02/23/2012
AARP Study Says Price of Popular Drugs Rose 26%
New York Times 03/06/2012
The French health care system and its costs, comparison with the American system of health care.
06/28/2007
The rising costs of the French system and its concept and performance. Efforts to meet rising costs and rise of the "mutuals." Healthcare in France is at about 11% of GNP compared to 16% in the USA, with 50 million uninsured in the US and 99% of 64 million people of France covered. Pricing of pharmaceutical products and healthcare services remains a major unsolved problem in the U.S.
Grouped Articles
The Soaring Cost of a Simple Breath
New York Times 10/12/2013
New York Times 12/21/2013
The French Lesson in Health Care
BusinessWeek 06/28/2007
New York Times 07/14/2007
In Holland, Some See Model For U.S. Health-Care System
Wall Street Journal 09/06/2007
Maker of Lipitor Digs In to Fight Generic Rival
New York Times 11/03/2007
Austerity cuts and pricing for pharmaceutical products in Europe
01/11/2010
The pricing practices for healthcare and pharmaceutical products in Europe during the eurozone debt crisis. Government initiative to limit pricing.
Grouped Articles
Austerity in Europe Puts Pressure on Drug Companies
New York Times 02/23/2012
Why an MRI costs $1,080 in America and $280 in France - The Washington Post
Washington Post 03/05/2012
AARP Study Says Price of Popular Drugs Rose 26%
New York Times 03/06/2012
Europe Drug Makers Seek Deal on Crisis Pricing
Wall Street Journal 06/25/2012
Large Price Jumps Reported for Small but Vital Drugs
New York Times 01/11/2010
Developing new solutions to the problem of escalating health care costs in the U.S.
01/31/2008
New solutions are being developed and new ideas being tried to bring down health care costs. In many case quality can improve at lower cost or the similiar results delivered for lower cost with some other advantages inpatient focussed healthcare that improve outcomes. Pricing of pharmaceutical products and healthcare services as the major unsolved problem in the U.S.
Grouped Articles
The Soaring Cost of a Simple Breath
New York Times 10/12/2013
New York Times 12/21/2013
Economy Led to Cuts in Use of Health Care, Study Says
New York Times 08/16/2010
Digital Records May Not Cut Health Costs, Study Cautions
New York Times 03/05/2012
Health Care: Obama's Budget Skimps on Cost-Cutting
BusinessWeek 03/05/2009
Hospitals Merge Design and Building to Cut Costs
New York Times 04/15/2009
Large legal settlements in the pharmaceutical industry.
10/25/2006
The settlements also involve drug pricing and marketing.
Grouped Articles
Drug Firms Curb Ties to Doctors
Wall Street Journal 12/18/2013
In Guilty Plea, OxyContin Maker to Pay $600 Million
New York Times 05/10/2007
Glaxo Sues Abbott Labs Over AIDS Drug Pricing
Wall Street Journal 11/09/2007
Drug Companies Face Political, Scientific Attacks
Wall Street Journal 01/23/2008
Drug Industry to Announce Revised Code on Marketing
New York Times 07/10/2008
Drug Approval Is Not a Shield From Lawsuits, Justices Rule
New York Times 03/05/2009
The struggle to get legislation passed to allow importation of drugs.
01/23/2008
Failure of the Byron Dorgan legislation by 9 votes in the Senate even thogh a coalition of Democrats and Republicans support it, with the Obama Administration opposing it. President Obama turns his back on action that he supported to help Americans hurt hig prescription costs, after pharmaceutial industry lobbyists are able to influence the Obama administration. Just as in the banking industry the Obama adminsitration is letting lobbyists influence its policies.
Grouped Articles
President Obama writes a new health reform prescription
Washington Post 12/16/2009
Wall Street’s resurgent prosperity frustrates its claims, and Obama’s - The Washington Post
Washington Post 11/07/2011
What caused the financial crisis? The Big Lie goes viral - The Washington Post
Washington Post 11/07/2011
A grim diagnosis for our ailing U.S. health care system - The Washington Post
Washington Post 11/28/2011
AARP Study Says Price of Popular Drugs Rose 26%
New York Times 03/06/2012
White House visitor logs show lobbying going strong - The Washington Post
Washington Post 05/21/2012
The U.S. FDA and a pathway for developing biosimilar drugs to reduce healthcare cost
02/10/2012
Grouped Articles
FDA Sets Path for Biotech Drug Copies
Wall Street Journal 02/10/2012
AARP Study Says Price of Popular Drugs Rose 26%
New York Times 03/06/2012
Biotech Drugs Still Won't Copy
Wall Street Journal 02/27/2013
Asthma pharmaceutical medications and the skyrocketing cost of health care in the U.S.
03/06/2012
Inhalers for asthma and drugs for asthma cost many times more in the U.S. compared to Europe and India, making it impossible for ordinary American families to afford needed treatment for children that affluent families take for granted. Even affluent or upper middle class families find the cost of these inhalers shocking compared to how little they cost in Europe and India.
Grouped Articles
The Soaring Cost of a Simple Breath
New York Times 10/12/2013
The High Cost of Asthma in America
New York Times 10/15/2013
AARP Study Says Price of Popular Drugs Rose 26%
New York Times 03/06/2012
India's Supreme Court and Novatis leukemia drug Gleevec
03/06/2012
The issues of what drugs are patentable in India,"evergreening" for patents, and public health concerns throughout developing countries, that are now before the Indian Supreme Court. India permitted the patenting of drugs only since 2005 under a WTO agreement, and there are restrictions on "evergreening," or small modifications of existing drugs for marketing. Novartis and other pharmaceutical companies aim to use the case to restrict Indian generic pharmaceuticals manufacturers from coming up with lowcost versions of new drugs. The leukemia treatment developed by Novartis costs over $70,000, by comparison Indian generic manufacturers can make a version of this for $2500.
Grouped Articles
India Orders Bayer to License Patented Cancer Drug
New York Times 03/12/2012
Indiaâs Supreme Court to Hear Dispute on Drug Patents
New York Times 03/06/2012
AARP Study Says Price of Popular Drugs Rose 26%
New York Times 03/06/2012
Three Days Of Hearings Yield Five Take-Aways
Wall Street Journal 03/29/2012
Top Court in India Rejects Novartis Drug Patent
New York Times 04/01/2013
Innovation and the pricing of drugs in the U.S. by the pharmaceutical companies.
06/09/2007
Will drug innovation be affected adversely by price reductions in the USA? No say experts as it is a globalized industry and innovation takes place in labs around the world. And the pricing reforms, as in Britian and Germany, can actually encourage R&D for effective drugs with good cost relationships; when comparitive effectiveness of drugs and cost benefit analyses is used in pricing reforms. Pricing of pharmaceutical products and healthcare services is the major unsolved problem in the U.S.
Grouped Articles
The Soaring Cost of a Simple Breath
New York Times 10/12/2013
New Medicines Emerge, but Few Blockbusters
Wall Street Journal 12/16/2013
New York Times 12/21/2013
FDA Approves Cholesterol Drug From Regeneron, Sanofi
Wall Street Journal 07/25/2015
Washington Post 09/22/2015
Settlement May Cut Drug Prices
Wall Street Journal 06/09/2007
Pharmaceutical company pricing in the U.S. and Europe
11/09/2007
The pricing of pharmaceutical products and healthcare services in the U.S. and Europe.
Grouped Articles
The Soaring Cost of a Simple Breath
New York Times 10/12/2013
Glaxo Sues Abbott Labs Over AIDS Drug Pricing
Wall Street Journal 11/09/2007
India Prepares EU Trade Complaint
Wall Street Journal 08/06/2009
Democrats Say No to Cost Cap for Drug Makers
New York Times 08/07/2009
Economist 08/27/2009
Large Price Jumps Reported for Small but Vital Drugs
New York Times 01/11/2010
Pricing of healthcare services and pharmaceuticals as the biggest problem in funding healthcare in the U.S.
01/31/2008
The cost of most healthcare services are double or higher in the U.S. than in Canada, Germany, France and Japan. By not bringing prices in line with the price in other major developed countries, the U.S. is effectively defunding infrastructure, R&D, education and other important means of improving competitiveness say experts. The methods of setting price present in these countries are notably absent in the U.S. The Obama healthcare bill and before that the Bush Medicare Prescription Drug Benefit simply leave this problem unaddressed.
Grouped Articles
Cuts Would Only Shift Health-Care Costs
Wall Street Journal 07/13/2011
Bayonne Medical Center Has Highest U.S. Billing Rates
New York Times 05/16/2013
The Soaring Cost of a Simple Breath
New York Times 10/12/2013
New York Times 12/21/2013
Economy Led to Cuts in Use of Health Care, Study Says
New York Times 08/16/2010
Washington Post 09/22/2015
Western pharmaceutical company growth strategies.
07/09/2007
As sales growth slows in developed countries, pricing drops, and drug development is weak, the search for new avenues for growth.
Grouped Articles
Glaxo's Garnier Is Taking the Heat
Wall Street Journal 07/09/2007
Glaxo to Weigh Results Of New Diet Pill
Wall Street Journal 10/24/2007
Prescription-Drug Sales Growth Is Expected to Slow
Wall Street Journal 11/01/2007
BusinessWeek 12/05/2007
Osteoporosis Drug Is Amgen's Hope For a Strong Future
Wall Street Journal 12/14/2007
Glaxo Becomes Master of Reinventing Drugs
Wall Street Journal 04/17/2008
Costs of America's healthcare system and services compared with other European countries
01/31/2008
The costs of American health care per patient is double that of some European countries with poorer results in many critical areas of medical services. The burden on society as a whole and the lack of incentive for providers and patients to take action. Pricing of healthcare and pharmaceuticals as the major unsolved problem in the U.S.
Grouped Articles
The Soaring Cost of a Simple Breath
New York Times 10/12/2013
New York Times 12/21/2013
Economy Led to Cuts in Use of Health Care, Study Says
New York Times 08/16/2010
Patients’ Costs Skyrocket; Specialists’ Incomes Soar
New York Times 01/18/2014
A grim diagnosis for our ailing U.S. health care system - The Washington Post
Washington Post 11/28/2011
Four Deficit Myths and a Frightening Fact
Wall Street Journal 01/19/2012
Vytorin study and the controversy over drug company marketing and pricing tactics.
12/17/2007
Merck sells Vytorin a combination of Zocor and Zetia for a expensive price touting benefits that may not exist according to its own study when generic Zocor can be bought for $6 for 30 days supply.
Grouped Articles
Stakes Remain High in Merck, Schering-Plough Drug Study
Wall Street Journal 12/17/2007
Drug Has No Benefit in Trial, Makers Say
New York Times 01/14/2008
Study Missteps Threaten Turnaround at Schering
Wall Street Journal 01/17/2008
Heart Group Backs Drug Made by Ally
New York Times 01/24/2008
AARP Study Says Price of Popular Drugs Rose 26%
New York Times 03/06/2012
Anemia drug made billions, but at what cost? - The Washington Post
Washington Post 07/20/2012
Pharmaceutical companies with Generics products are changing the marketplace.
07/26/2005
With growing demand for low cost affordable drugs the growth in sales of generics.
Grouped Articles
Indian Drug Maker Vies for Betapharm
Wall Street Journal 02/09/2006
Branded Drugs Settling More Generic Suits
Wall Street Journal 01/17/2006
Generics Eat Into Pfizer's Profit; Costs Offset Novartis Sales Gain
Wall Street Journal 01/20/2006
As Generics Pummel Its Drugs, Pfizer Faces Uncertain Future
Wall Street Journal 01/05/2006
Teva to Acquire Ivax, Another Maker of Generic Drugs
New York Times 07/26/2005
Wall Street Journal 07/26/2005
Failure to control overbilling by pharmaceutical companies, medical equipment and device makers in the health reform bill.
12/10/2009
Only $10 million annual increase to control fraud has been allocated in the bill. Its not likely to do much to control the overbilling and may be one more reason the health care reform bill will be a failure in controlling costs. Pricing of pharmaceutical products and healthcare services as the major unsolved problem in the U.S.
Grouped Articles
New York Times 12/21/2013
BusinessWeek 12/10/2009
How the Senate bill would contain the cost of health care : The New Yorker
New Yorker 01/04/2010
In Battle Over Health Law, Math Cuts Both Ways
New York Times 01/07/2011
House Approves Health Law Repeal
Wall Street Journal 01/20/2011
A grim diagnosis for our ailing U.S. health care system - The Washington Post
Washington Post 11/28/2011
Britain's National Institute forHealth and Clinical Excellence (NICE) and reviews of drugs for costs and benefits- 2010-2013
10/01/2011
Reviews of drugs for Lupus and MS resulting in turning them down because of high costs and modest efficacy.
Grouped Articles
U.K. Pushback on Glaxo Drug Price
Wall Street Journal 10/01/2011
A grim diagnosis for our ailing U.S. health care system - The Washington Post
Washington Post 11/28/2011
AARP Study Says Price of Popular Drugs Rose 26%
New York Times 03/06/2012
Cost of Brand-Name Prescription Medicines Soaring
New York Times 11/28/2012
We took a different way to help millions around the world build educated informed mindsets that affects and shapes their lives. For a future that is open, global and digital, with everyone having access to high quality information. We believe in the renewal of America, renewal of Europe, the renewal of India, the rest of Asia, Latin America and Africa. The renewal of our supply chains, health, education, infrastructure, as we rebuild our countries after the pandemic. Literacy and knowledge we believe cannot thrive and grow in a world of web bots, web crawlers, or AI. This requires human curiosity, human learning, and human imagination. We take as inspiration the saying- “One has to be free, and as broad as sky. One has to have a mind that is crystal clear, only then can truth shine in it.” Every contribution whether big or small is precious- in this crisis and ahead.
Support Lyrarc from as small as $1
Terms and Conditions | Copyright Policy | Privacy Policy | Contact Us
